Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.35 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1691141 | 0.96 | CYP4F2 (0.41) | SMN1; SMN2KMT2AMEN1POLBKDM4E | |
| SCHEMBL2185965 | 0.94 | CYP4F2 (0.40) | SMN1; SMN2KMT2AMEN1POLBKDM4E | |
| SCHEMBL164041 | 0.91 | ALDH1A1 (0.40) | SMN1; SMN2KMT2AMEN1POLBALDH1A1 | |
| SCHEMBL2289682 | 0.85 | SMN1; SMN2 (0.44) | SMN1; SMN2KMT2AMEN1POLBKDM4E | |
| SCHEMBL29210884 | 0.84 | CYP4F2 (0.46) | SMN1; SMN2KMT2AMEN1POLBKDM4E | |
| SCHEMBL6782433 | 0.82 | TSHR (0.42) | SMN1; SMN2KMT2AMEN1POLBALDH1A1 | |
| SCHEMBL13268736 | 0.82 | OPRM1 (0.50) | SMN1; SMN2KMT2AMEN1POLBKDM4E | |
| SCHEMBL12140578 | 0.82 | SMN1; SMN2 (0.36) | SMN1; SMN2KMT2AMEN1POLBALDH1A1 | |
| SCHEMBL425037 | 0.82 | SMN1; SMN2 (0.41) | SMN1; SMN2KMT2AMEN1POLBKDM4E | |
| SCHEMBL1633342 | 0.82 | SMN1; SMN2 (0.41) | SMN1; SMN2KMT2AMEN1POLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5076831-A | Herbicides | BASF AKTIENGESELLSCHAFT (DE) | 1991-12-31 | — | — | US | claimed |
| US-12617867-B2 | Ligand-drug conjugate of exatecan analogue, preparation method therefor and application thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2026-05-05 | — | — | US | disclosed |
| US-20250339411-A1 | GLP-1R AGONIST COMPOUND AND USE THEREOF | CHONGQING PHARMACEUTICAL RES INSTITUTE CO LTD (CN) | 2025-11-06 | — | — | US | disclosed |
| US-12419874-B2 | GLP-1R agonist compound and use thereof | CHONGQING PHARMACEUTICAL RESEARCH INSTITUTE CO., LTD. (CN) | 2025-09-23 | — | — | US | disclosed |
| US-20250195481-A1 | GLP-1R AGONIST COMPOUND AND USE THEREOF | CHONGQING PHARMACEUTICAL RESEARCH INSTITUTE CO., LTD. (CN) | 2025-06-19 | — | — | US | disclosed |
| US-12331026-B2 | Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors | NIKANG THERAPEUTICS, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| WO-2025097835-A1 | GLP-1R AGONIST COMPOUND AND USE THEREOF | 重庆医药工业研究院有限责任公司 | 2025-05-15 | — | — | WO | disclosed |
| EP-4536363-A1 | SULFAMIDE DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | Nikang Therapeutics, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| US-20240415847-A1 | BETA-LACTAMASE INHIBITORS AND USES THEREOF | ARIXA PHARMACEUTICALS, INC. (US) | 2024-12-19 | — | — | US | disclosed |
| EP-3860999-B9 | DERIVATIVES OF RELEBACTAM AND USES THEREOF | ARIXA PHARMACEUTICALS INC (US) | 2024-08-14 | — | — | EP | disclosed |
| EP-1836183-A2 | SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS | Galileo Pharmaceuticals, Inc. (US) | 2007-09-26 | — | — | EP | disclosed |
| EP-1703908-A1 | ARYL SULFONAMIDE COMPOUNDS AND USES RELATED THERETO | Amgen Inc. (US) | 2006-09-27 | — | — | EP | disclosed |
| WO-2006065686-A2 | SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS | GALILEO PHARMACEUTICALS, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
| US-20060128790-A1 | Spiro derivatives as lipoxygenase inhibitors | GALILEO PHARMACEUTICALS, INC. | 2006-06-15 | — | — | US | disclosed |
| US-20050277649-A1 | Aryl sulfonamide compounds and uses related thereto | AMGEN SF, LLC (US) | 2005-12-15 | — | — | US | disclosed |
| WO-2005063247-A1 | ARYL SULFONAMIDE COMPOUNDS AND USES RELATED THERETO | AMGEN INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| US-5076831-A | Herbicides | BASF AKTIENGESELLSCHAFT (DE) | 1991-12-31 | — | — | US | disclosed |
| US-5049696-A | Enzyme inhibitors | MERCK & CO., INC. (US) | 1991-09-17 | — | — | US | disclosed |
| US-4847306-A | ENZYME INHIBITORS | MERCK & CO., INC. (US) | 1989-07-11 | — | — | US | disclosed |
| EP-0245004-A2 | Antihypercholesterolemic compounds | MERCK & CO. INC. (US) | 1987-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250195481-A1 | GLP-1R AGONIST COMPOUND AND USE THEREOF | GLP1R, GIPR, GPR119 | SMN1; SMN2 2057/4885KMT2A 2575/4885MEN1 891/4885 |
| US-12617867-B2 | Ligand-drug conjugate of exatecan analogue, preparation method therefor and application thereof | EGFR, CCKAR, MET | SMN1; SMN2 4421/4885KMT2A 1590/4885MEN1 1773/4885 |
| US-12331026-B2 | Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors | CDK2, CCNK, CCNI | SMN1; SMN2 1215/4885KMT2A 905/4885MEN1 2859/4885 |
| US-20050277649-A1 | Aryl sulfonamide compounds and uses related thereto | SULT2A1, ARSA, SULT1A1 | SMN1; SMN2 3200/4885KMT2A 896/4885MEN1 4139/4885 |
| US-20250339411-A1 | GLP-1R AGONIST COMPOUND AND USE THEREOF | GLP1R, GIPR, GPR119 | SMN1; SMN2 2057/4885KMT2A 2575/4885MEN1 891/4885 |
| US-20060128790-A1 | Spiro derivatives as lipoxygenase inhibitors | ALOX15B, ALOX5, ALOX15 | SMN1; SMN2 4254/4885KMT2A 3967/4885MEN1 4420/4885 |
| US-20240415847-A1 | BETA-LACTAMASE INHIBITORS AND USES THEREOF | GAA, LCT, MGAM | SMN1; SMN2 3557/4885KMT2A 3236/4885MEN1 3937/4885 |
| US-12419874-B2 | GLP-1R agonist compound and use thereof | GLP1R, GIPR, GPR119 | SMN1; SMN2 2057/4885KMT2A 2575/4885MEN1 891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.